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Background: In order to analyze postoperative liver regeneration following hepatic resection after chemotherapy,
we retrospectively investigated the differences in liver regeneration by comparing changes of residual liver volume
in three groups: a living liver donor group and two groups of patients with colorectal liver metastases who did and
did not undergo preoperative chemotherapy.
Methods: This study included 32 patients who had at least segmental anatomical hepatic resection. Residual liver
volume, early postoperative liver volume, and late postoperative liver volume were calculated to study the changes
over time. From the histopathological analysis of chemotherapy-induced liver disorders, the effect on liver
regeneration according to the histopathology of noncancerous liver tissue was also compared between the two
colorectal cancer groups using Kleiner’s score for steatohepatitis grading {Hepatology, 41(6):1313–1321, 2005} and
sinusoidal obstruction syndrome (SOS) grading for sinusoidal obstructions {Ann Oncol, 15(3):460–466, 2004}.
Results: Assuming a preoperative liver volume of 100%, mean late postoperative liver volumes in the three groups
(the living liver donor group and the colorectal cancer groups with or without chemotherapy) were 91.1%, 80.8%,
and 81.3%, respectively, with about the same rate of liver regeneration among the three groups. Histopathological
analysis revealed no correlation between either the Kleiner’s scores or the SOS grading and liver regeneration.
Conclusions: As estimated by liver volume, the level of liver regeneration was the same in normal livers, tumor-
bearing livers, and post-chemotherapy tumor-bearing livers. Liver regeneration was not adversely affected by the
extent to which steatosis or sinusoidal dilatation was induced in noncancerous tissue by chemotherapy in patients
scheduled for surgery.Background
Colorectal cancer remains a major cause of cancer
deaths throughout the world. Survival rates are strongly
related to how extensively distant metastases are present.
The liver is often the site of distant metastatic involve-
ment. Approximately 25% of patients reportedly have
liver metastases when diagnosed with colorectal cancer,
and 25–35% of patients who have undergone resection
for primary lesions show liver metastases [1].
Hepatic resection is potentially curative in colorectal
cancer patients with liver metastases. In resectable cases, a
5-year survival rate of more than 50% can be anticipated
[2]. However, only 15–20% of patients are considered* Correspondence: takahara@iwate-med.ac.jp
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reproduction in any medium, provided the orresectable. This is because the liver metastases have spread
to both lobes or because adequate residual liver volume
cannot be ensured. Meanwhile, chemotherapy is an option
in other patients who are considered unresectable. Some of
these patients become resectable after conversion chemo-
therapy, and the importance of multimodal therapy that
combines conversion chemotherapy and surgical resection
in such cases has been reported [3,4].
Intra- and extrahepatic recurrences are often detected
after hepatic resection. The usefulness of neoadjuvant
chemotherapy in advance of hepatic resection is being
increasingly claimed, but its appropriateness is contro-
versial. Some advantages of neoadjuvant chemotherapy
are that the shrinkage of liver metastases enables R0
resection [5] and that such neoadjuvant chemotherapy
prior to hepatic resection can eradicate micro-lesionsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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some disadvantages are that chemotherapy causes the
potential for more operative complications [8], greater
hepatic impairments [9-11], and procedural difficulties
in the event of complete response (CR) on imaging [12].
And it has not yet been decided how long the patients
had undergone neoadjuvant chemotherapy. Preoperative
chemotherapy may result in chemotherapy-related liver
disorders, particularly in colorectal cancer patients with
liver metastases [13]. Steatohepatitis and sinusoid obstruc-
tion are considered common liver disorders. Steatohepatitis
is said to be strongly correlated to irinotecan, while
sinusoidal obstruction is said to be strongly correlated
to oxaliplatin. These disorders may also result in more
perioperative complications [10-14].
The indocyanine green retention rate at 15 min
(ICGR15) is one of some useful measures of preoperative
hepatic functional reserve prior to hepatic resection, and
the extent of hepatic resection in hepatitis and obstructive
jaundice has been amply reported to date [15-17]. Few
reports have described methods for rigorously assessing
the hepatic reserve after preoperative chemotherapy in
colon cancer patients with liver metastases.
The key point of this study was that the level of liver re-
generation in tumor-bearing livers and post-chemotherapy
tumor-bearing livers was revealed to be consistent with
that of normal livers by liver volume estimation. Another
important point was that we monitored the regeneration
rate of the liver from the living liver donor as a control.
Methods
This study included 32 patients who had anatomical
hepatic resection. We compared three groups, composed
of 17 colorectal cancer patients with liver metastases who
had undergone at least segmental anatomical hepatic
resection (8 patients with and 9 patients without preopera-
tive chemotherapy) and 15 patients in a living liver donor
transplantation group in our department since January
2008. The preoperative chemotherapy regimen was
oxaliplatin-based in six subjects, irinotecan-based in one




mFOLFOX6 + BEV 3 (37.5)
MFOLFOX6 + CET** 1 (12.5%)
MFOLFOX6→sLV + 5FLU 1 (12.5%)
FOLFIRI 1 (12.5%)
mFOLFOX6→FOLFIRI 1 (12.5%)
BEV*: bevacizumab, CET**: cetuximab.subject. Modern regimens include biologic agents or “anti-
bodies” such as bevacizumab or cetuximab. The preope-
rative washout was a minimum of 4 weeks (mean, 11.6
weeks) (Table 1). In addition, in colon cancer patients with
multiple liver metastases, at least 30% residual liver
volume must be ensured, and hepatic resection cannot be
performed any sooner than 4 weeks after chemotherapy.
This study is the retrospective clinical one planned by
the Department of Surgery, Iwate Medical University
School of Medicine. Patient data were retrospectively
gained from our database for colorectal liver metastases
patients and living liver donors.
Liver volume analysis
Preoperative liver volume, residual liver volume, early
postoperative liver volume, and late postoperative liver
volume in each group were calculated and analyzed. The
early postoperative period was defined as about 1 month
postoperatively (median 1.1, range 1.0–1.1), and the late
postoperative period was defined as about 6 months post-
operatively (median 6.2, range 5.8–6.3). Liver volumes
were measured using a SYNAPSE VINCENT volume
analyzer (Fujifilm Co., Ltd., Japan) to measure the volume
of reconstructed three-dimensional liver images based on
CT performed at each analysis time point, and changes
over time were compared among the three groups.
To exclude the effects of the preoperative tumor loads,
we have withdrawn the volume of the liver metastases
from the total liver volume to calculate a “functional liver
volume.” The liver regeneration rate versus the “functional
liver volume” was also calculated in tumor-bearing
livers (n = 9) and post-chemotherapy tumor-bearing
livers (n = 8) at each analysis time point.
Histopathological analysis
Chemotherapy-induced hepatic impairment was histo-
pathologically analyzed between groups of subjects who
had and had not undergone preoperative chemotherapy. All
histopathological assessments were undertaken by the same
pathologist. Steatohepatitis was assessed by grading the
severity of each parameter (steatosis, fibrosis, inflammation,er of course), and time before hepatectomy
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calculate the total score (Table 2) [18]. Sinusoidal obstruc-
tions were assessed using the three-stage grading for sinus-
oidal obstruction syndrome (SOS), where centrilobular
sinusoidal obstruction of no more than one-third was
considered “mild,” and sinusoidal obstructions of two-
thirds or more of both lobes were considered “severe,”
with “moderate” in between the two [14].
Operation procedure
Hepatectomy was performed anatomically, using the
hepatic vein as the landmark for dissection, where theTable 2 Grading the severity of each parameter using
Kleiner’s score [1]
Score








Microvesicular steatosis Not present 0
Presented 1












<2 foci per 200× field 1
2–4 foci per 200× field 2
>4 foci per 200× field 3
Liver cell injury Ballooning None 0








None to rare 0
Many 1
Other findings Mallory's hyaline None to rare 0
Many 1
Glycogenated nuclei None to rare 0
Many 1surgeon made use of CUSA and the first assistant made use
of a coagulation hemostatic device, with the intention of
achieving the least possible congestion in the residual liver.
Statistics
Continuous variables are expressed as mean ± standard
error of the mean. Differences among the three groups
were analyzed by the Kruskal-Wallis test, as appropriate.
Statistical significance was accepted at p < 0.05. Data ana-
lysis was performed with Stat-View 5.0 (SAS Institute,
Cary, NC).
Results
The mean ages in the living liver donor group, non-
chemotherapy group, and chemotherapy group were
36.6 years (range, 20–57 years), 68.0 years (range, 53–78
years), and 59.6 years (range, 42–66 years), respectively,
and the male:female ratios were 8:7, 8:1, and 6:2,
respectively (Table 3).
The changes over time in liver volume in each group
were graphed (Figure 1). Differences were expressed as the
rate of increase assuming a preoperative liver volume of
100%. In the living liver donor group, the mean posto-
perative residual liver volume was 47.7% of the total
preoperative liver volume, increasing about 28% to 75.7% in
the early postoperative period, with liver regeneration up to
91.1% by the late postoperative period. In the non-
chemotherapy group, the mean postoperative residual liver
volume was 52.7%, increasing to 72.0% in the early postop-
erative period, revealing approximately 20% liver regene-
ration. Liver regeneration up to 80.8% was ultimately found
by the late postoperative period. In the chemotherapy
group, the mean residual liver volume was about 49.4% of
the total preoperative liver volume, with an approximately
18% increase in liver volume, to 67.9% in the early posto-
perative period. Liver regeneration up to about 81.3% was
found by the late postoperative period. The mean liver
volume in the three groups is shown in a graph (Figure 1).
The results showed that the changes over time in liver
volume were similar in all three groups. The rate of liver re-
generation was about the same in the three groups. In
tumor-bearing liver group (n = 9), the mean postoperative
residual liver volume was 54.4% of the “functional liver vol-
ume,” increasing to 73.2% in the early postoperative period,
with liver regeneration up to 85.5% by the late postopera-
tive period. In post-chemotherapy tumor-bearing liver
group (n = 9), the mean postoperative residual liver vol-
ume was 56.9% of the “functional liver volume,” increasing
to 80.4% in the early period and 97.7% in the late period.
The results for liver regeneration versus the “functional
liver volume” in the two groups are shown as almost even.
The liver regeneration rate versus the hepatic resection
volume was also calculated. In the living liver donor group,
a mean liver regeneration of 54.4% was found in the early
Table 3 Profiles of the enrolled patients
Living liver donor (n = 15) Without chemotherapy (n = 9) Without chemotherapy (n = 8)
Age (mean ± SE*) 36.6 ± 3.1 68.0 ± 2.3 59.6 ± 3.0
Sex, M/F 8/7 8/1 6/2
Operative method
(hepatectomy)
Major 15 6 6
Minor 3 2
Operative time (min) 381.6 ± 9.5 238.2 ± 28.8 305.9 ± 25.4
(mean ± SE) 294.2 ± 36.7 450.9 ± 102.6 595.0 ± 249.7
Blood loss (cc) (mean ± SE) 8.4 ± 0.6 10.1 ± 1.3 27.6 ± 12.3
(mean ± SE) 1(Clavia IIIa)/0 2(C lavian IIa)/0 1(Clavian IIIa)/0
Morbidity/mortality
Continuous variables are expressed as mean ± SE* (standard error of the mean).
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the late postoperative period. In the nonchemotherapy
group, a mean liver regeneration of 36.3% was found in the
early postoperative period, and a mean regeneration of
30.4% was found in the late postoperative period. In the
chemotherapy group, a mean liver regeneration of 57.5%
was found in the early postoperative period, and 36.5% re-
generation was found in the late postoperative period. The
results for liver regeneration versus hepatic resection vol-
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Figure 1 The changes over time in liver volume among the three groThe relationship between ICG R15 and liver regeneration
is shown (Figure 2). The liver regeneration rate (%) is de-
fined as how the percentage of the total liver is increasing
in the early postoperative period. No correlation was found
between ICG R15 and the liver regeneration rate in any of
the three groups (not in the living liver donor group or the
two groups of colorectal cancer patients with liver metasta-
ses who had or had not undergone chemotherapy). Some
patients showed a relatively favorable hepatic reserve des-
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Figure 2 The relationship between ICG R15 and
liver regeneration.
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regeneration rates that were virtually the same as in other
patients, despite an unfavorable hepatic reserve.
The results of the histopathological analyses of liver
regeneration in colorectal cancer patients with liver
metastases in the two groups (with and without preopera-
tive chemotherapy) are shown (Figure 3). No correlation
between SOS grading and the liver regeneration rates was
found. Likewise, no correlation between Kleiner’s score
and the liver regeneration rates was found. Some patients
were assigned severe SOS grades, yet they showed a liver
regeneration rate that was equal to or better than that in
other patients. In some patients with a high Kleiner’s score
(5 points or more), even those with chemotherapy-
associated steatohepatitis (CASH), the liver regenerated
more readily than in other patients.
Discussion
A number of reports have indicated that conversion
chemotherapy in colorectal cancer patients with multiple
liver metastases allows the disease to be downstaged, thus
rendering the disease resectable in such patients, and when
combined with resection, contributing to improved sur-
vival. On the other hand, preoperative chemotherapy has


































Figure 3 The relationships between the histopathological analyses ansuch as steatohepatitis and sinusoidal dilatation. Such liver
disorders may compromise postoperative liver regeneration,
but other reports have suggested that surgical outcomes or
complications are not adversely affected [19-25]. To analyze
the effect on liver regeneration of chemotherapy-induced
liver disorders, the postoperative rate of increase in liver
volume in living liver donors (normal livers) and the post-
operative rate of increase in liver volume for colon cancer
patients with liver metastases in the chemotherapy and
nonchemotherapy groups were investigated on the basis of
volume in this study.
ICG R15 plays an important role in assessing hepatic
reserve or determining the extent of hepatic resection vol-
ume in hepatocellular carcinoma. This study investigated
whether, as a measure of hepatic reserve following
preoperative chemotherapy, this ICG R15 or the severity of
histopathological disorders that have been reported thus far
can or cannot predict the rate of increase in liver volume.
This study, which is characterized by a small number of
patients and a lack of serious postoperative complications
in any of the groups, was a retrospective analysis, and the
conclusions are by no means definitive. In addition, in
colon cancer patients with multiple liver metastases, a
residual liver volume of at least 35% must be ensured, and
hepatic resection cannot be performed any sooner than 4
weeks after chemotherapy [26]. Hepatectomy was per-
formed anatomically, using the hepatic vein as the land-
mark for dissection, where the surgeon made use of CUSA
and the first assistant made use of a coagulation hemostatic
device, with the intention of achieving the least possible
congestion in the residual liver. Donor resection was by
hepatectomy with uninterrupted blood inflow, whereas the
Pringle method was used in approximately 40% of the colo-
rectal cancer patients with liver metastases. Among the
three groups, no significant differences in postoperative
liver function (such as protein synthesis capacity or nutri-
tional state) were noted in either the early or late postoper-
ative periods (Table 4). The postoperative rate of increase
in liver volume was about the same in the three groups, as















Table 4 Postoperative liver function
Laboratory data (mean ± SE) Living liver donor (n = 5) Without chemotherapy (n = 9) With chemotherapy (n = 8) p value*
T-Bill (mg/dl)
Preoperative 0.69 ± 0.05 0.77 ± 0.18 0.45 ± 0.04 0.03
5 postoperative days 1.64 ± 0.44 1.42 ± 0.27 1.28 ± 0.27 0.81
Early period 0.93 ± 0.20 0.80 ± 0.21 1.60 ± 1.02 0.61
Late period 0.79 ± 0.11 0.72 ± 0.08 0.74 ± 0.08 0.97
PT-INR
Preoperative 0.97 ± 0.02 0.96 ± 0.02 0.97 ± 0.03 0.82
5 postoperative days 1.11 ± 0.03 1.12 ± 0.03 1.10 ± 0.04 0.81
Early period 1.07 ± 0.05 1.01 ± 0.03 1.05 ± 0.04 0.68
Late period 0.95 ± 0.01 0.94 ± 0.03 1.02 ± 0.03 0.19
Plt (×103μl)
Preoperative 25.7 ± 1.6 22.5 ± 1.3 25.3 ± 1.9 0.35
5 postoperative days 19.7 ± 1.4 16.8 ± 1.3 16.8 ± 2.0 0.4
Early period 25.7 ± 1.9 16.8 ± 1.3 26.6 ± 3.7 0.16
Late period 22.1 ± 0.9 20.2 ± 2.9 19.4 ± 2.2 0.1
Alb (g/Dl)
Preoperative 4.3 ± 0.1 4.0 ± 0.2 3.9 ± 0.2 0.22
5 postoperative days 3.1 ± 0.1 3.1 ± 0.1 2.9 ± 0.1 0.55
Early period 3.6 ± 0.2 3.5 ± 0.2 3.5 ± 0.2 0.74
Late period 4.2 ± 0.1 3.9 ± 0.2 3.4 ± 0.3 0.003
p values* compare variables by the Kruskal-Wallis test among the three groups.
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tions of liver generation such as younger age and no Pringle
maneuver, the level of liver regeneration was the same in
normal livers, tumor-bearing livers, and post-chemotherapy
tumor-bearing livers, as estimated by liver volume [27]. To
exclude the effects of the preoperative tumor loads, we have





























Figure 4 The results for liver regeneration versus the functional liverliver volume to calculate a “functional liver volume.” The
results for liver regeneration versus the “functional liver
volume” at the early postoperative period and late period
are shown as almost even not only in the tumor-bearing
two groups but also in the three groups involving the living
liver donor groups (Figure 4). ICG R15 levels and histo-







volume among the three groups.
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results.
It has been reported that preoperative chemotherapy does
not adversely affect surgical outcomes or surgically related
complications. In addition, the results of this study were de-
rived from the comparative analysis of postoperative liver
regeneration in living liver donors (normal livers). Both
sources suggest that preoperative chemotherapy is a safe
and effective option, provided that adequate residual liver
volume is ensured, that the dosing regimen is followed
(including preoperative chemotherapy washout in patients
scheduled for surgery), and that anatomical hepatic resec-
tion is performed in a way that ensures blood flow will be
controlled in the residual liver.
Conclusion
In conclusion, as estimated on the basis of liver volume, the
level of liver regeneration was the same among normal
livers, tumor-bearing livers, and post-chemotherapy tumor-
bearing livers. Liver regeneration was not adversely affected
by the extent to which sinusoidal dilatation or steatosis was
induced in noncancerous tissue by chemotherapy in
patients scheduled for surgery. Preoperative chemotherapy
may therefore be an effective option worth considering.
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